Benign prostatic hyperplasia and new treatment options – a critical appraisal of the UroLift system

Thomas Anthony McNicholas1–3 1Section of Urology, Royal Society of Medicine, London, UK; 2Urology Department, Lister Hospital, East and North Herts NHS Trust, Stevenage, UK; 3Faculty of Health and Human Sciences, University of Hertfordshire, Hatfield, Herts, UK Abstract: The prostatic ure...

Full description

Bibliographic Details
Main Author: McNicholas TA
Format: Article
Language:English
Published: Dove Medical Press 2016-05-01
Series:Medical Devices: Evidence and Research
Subjects:
Online Access:https://www.dovepress.com/benign-prostatic-hyperplasia-and-new-treatment-options-ndash-a-critica-peer-reviewed-article-MDER
_version_ 1818744345036062720
author McNicholas TA
author_facet McNicholas TA
author_sort McNicholas TA
collection DOAJ
description Thomas Anthony McNicholas1–3 1Section of Urology, Royal Society of Medicine, London, UK; 2Urology Department, Lister Hospital, East and North Herts NHS Trust, Stevenage, UK; 3Faculty of Health and Human Sciences, University of Hertfordshire, Hatfield, Herts, UK Abstract: The prostatic urethral lift procedure, more commonly known as UroLift, has been designed to improve male lower urinary tract symptoms while avoiding the complications and disadvantages of existing drug and surgical therapies. In particular, UroLift does not damage ejaculatory function or affect orgasmic sensation. It appears an option for men who wish to avoid long-term drug therapy, the side effects of drugs or surgery and who do not need or will not accept traditional surgical treatments. UroLift was introduced following a series of planned studies that led to US Food and Drug Administration approval in September 2013. UroLift has recently been approved by the UK National Institute for Clinical and Health Excellence (September 2015) as effective and safe and cost-effective for use in the UK health system. This review describes the device and the procedure and the evidence base that has led to those approvals. Keywords: UroLift, prostatic urethral lift, LUTS prostatic hyperplasia, minimally invasive, BPH
first_indexed 2024-12-18T02:42:49Z
format Article
id doaj.art-2cbc80d3f2bd4235b76d715f462fab39
institution Directory Open Access Journal
issn 1179-1470
language English
last_indexed 2024-12-18T02:42:49Z
publishDate 2016-05-01
publisher Dove Medical Press
record_format Article
series Medical Devices: Evidence and Research
spelling doaj.art-2cbc80d3f2bd4235b76d715f462fab392022-12-21T21:23:37ZengDove Medical PressMedical Devices: Evidence and Research1179-14702016-05-012016Issue 111512327006Benign prostatic hyperplasia and new treatment options – a critical appraisal of the UroLift systemMcNicholas TAThomas Anthony McNicholas1–3 1Section of Urology, Royal Society of Medicine, London, UK; 2Urology Department, Lister Hospital, East and North Herts NHS Trust, Stevenage, UK; 3Faculty of Health and Human Sciences, University of Hertfordshire, Hatfield, Herts, UK Abstract: The prostatic urethral lift procedure, more commonly known as UroLift, has been designed to improve male lower urinary tract symptoms while avoiding the complications and disadvantages of existing drug and surgical therapies. In particular, UroLift does not damage ejaculatory function or affect orgasmic sensation. It appears an option for men who wish to avoid long-term drug therapy, the side effects of drugs or surgery and who do not need or will not accept traditional surgical treatments. UroLift was introduced following a series of planned studies that led to US Food and Drug Administration approval in September 2013. UroLift has recently been approved by the UK National Institute for Clinical and Health Excellence (September 2015) as effective and safe and cost-effective for use in the UK health system. This review describes the device and the procedure and the evidence base that has led to those approvals. Keywords: UroLift, prostatic urethral lift, LUTS prostatic hyperplasia, minimally invasive, BPHhttps://www.dovepress.com/benign-prostatic-hyperplasia-and-new-treatment-options-ndash-a-critica-peer-reviewed-article-MDERUroliftprostatic urethral liftLower urinary tract symptoms (LUTS)MaleBenign prostatic hyperplasiaMinimally invasive surgical procedureProstateTherapyUrethra
spellingShingle McNicholas TA
Benign prostatic hyperplasia and new treatment options – a critical appraisal of the UroLift system
Medical Devices: Evidence and Research
Urolift
prostatic urethral lift
Lower urinary tract symptoms (LUTS)
Male
Benign prostatic hyperplasia
Minimally invasive surgical procedure
Prostate
Therapy
Urethra
title Benign prostatic hyperplasia and new treatment options – a critical appraisal of the UroLift system
title_full Benign prostatic hyperplasia and new treatment options – a critical appraisal of the UroLift system
title_fullStr Benign prostatic hyperplasia and new treatment options – a critical appraisal of the UroLift system
title_full_unstemmed Benign prostatic hyperplasia and new treatment options – a critical appraisal of the UroLift system
title_short Benign prostatic hyperplasia and new treatment options – a critical appraisal of the UroLift system
title_sort benign prostatic hyperplasia and new treatment options ndash a critical appraisal of the urolift system
topic Urolift
prostatic urethral lift
Lower urinary tract symptoms (LUTS)
Male
Benign prostatic hyperplasia
Minimally invasive surgical procedure
Prostate
Therapy
Urethra
url https://www.dovepress.com/benign-prostatic-hyperplasia-and-new-treatment-options-ndash-a-critica-peer-reviewed-article-MDER
work_keys_str_mv AT mcnicholasta benignprostatichyperplasiaandnewtreatmentoptionsndashacriticalappraisaloftheuroliftsystem